FDA approves first oral formulation of Miconazole

The FDA has approved Strativa Pharmaceuticals' Oravig (miconazole) buccal tablets for the treatment of oropharyngeal candidiasis (OPC), more commonly known as “thrush.” Oravig, which adheres to the gum, delivers miconazole antifungal medication directly at the local site of infection throughout the day with minimal systemic absorption. Says John A. MacPhee, Strativa President, "Oravig offers patients suffering from thrush a proven effective treatment in a discreet and convenient once-daily formulation." OPC is an oral fungal infection most common in individuals with weakened immune systems--particularly those with HIV/AIDS and those undergoing certain cancer treatments.

- here's the Strativa release

Suggested Articles

Takeda forged a feasibility pact to see whether it could pair a plasma-based therapy with Elektrofi's microparticle delivery tech.

RNA nanoparticles can squeeze into tumors and exit swiftly through the kidney, perfect for targeted delivery of cancer drugs, an OSU team says.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.